BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33933153)

  • 1. Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    Zheng Y; Li B; Pan D; Cao J; Zhang J; Wang X; Li X; Hou W; Bao D; Ren L; Yang J; Wang S; Qiu Y; Zhou F; Liu Z; Zhu S; Zhang L; Qing T; Wang Y; Yu Y; Wu J; Hu X; Shi L
    Breast Cancer Res; 2021 May; 23(1):53. PubMed ID: 33933153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
    De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
    Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of clinical
    Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
    Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
    González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
    Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.
    Maurer LM; Daley JD; Mukherjee E; Venier RE; Julian CM; Bailey NG; Jacobs MF; Kumar-Sinha C; Raphael H; Periyapatna N; Weiss K; Janeway KA; Mody R; Lucas PC; McAllister-Lucas LM; Bailey KM
    Cancer Res Commun; 2022 Apr; 2(4):220-232. PubMed ID: 36187937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity.
    Adamovich AI; Banerjee T; Wingo M; Duncan K; Ning J; Martins Rodrigues F; Huang KL; Lee C; Chen F; Ding L; Parvin JD
    PLoS Genet; 2019 Mar; 15(3):e1008049. PubMed ID: 30925164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
    Ozden O; Bishehsari F; Bauer J; Park SH; Jana A; Baik SH; Sporn JC; Staudacher JJ; Yazici C; Krett N; Jung B
    Sci Rep; 2016 May; 6():26273. PubMed ID: 27197561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
    Zhao W; Steinfeld JB; Liang F; Chen X; Maranon DG; Jian Ma C; Kwon Y; Rao T; Wang W; Sheng C; Song X; Deng Y; Jimenez-Sainz J; Lu L; Jensen RB; Xiong Y; Kupfer GM; Wiese C; Greene EC; Sung P
    Nature; 2017 Oct; 550(7676):360-365. PubMed ID: 28976962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
    Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
    PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
    De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
    Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    Shi Y; Jin J; Wang X; Ji W; Guan X
    Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.
    Li M; Yu X
    Cancer Cell; 2013 May; 23(5):693-704. PubMed ID: 23680151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
    Sabatier R; Adélaïde J; Finetti P; Ferrari A; Huiart L; Sobol H; Chaffanet M; Birnbaum D; Bertucci F
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1143-51. PubMed ID: 20842729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.
    Ratajska M; Matusiak M; Kuzniacka A; Wasag B; Brozek I; Biernat W; Koczkowska M; Debniak J; Sniadecki M; Kozlowski P; Klonowska K; Pilyugin M; Wydra D; Laurent G; Limon J; Irminger-Finger I
    Oncol Rep; 2015 Nov; 34(5):2609-17. PubMed ID: 26329992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.